Clinical Trials

Introgen Therapeutics reports fourth quarter 2001 expectations met

Published in Gene Therapy Weekly, March 14th, 2002

Introgen Therapeutics, Inc., (INGN) announced that its results for the quarter ended December 31, 2001, were consistent with its expectations, during which time Introgen reported progress in its clinical development program, clinical and regulatory infrastructure and manufacturing experience.

In September 2001 Introgen changed its fiscal year end from June 30 to December 31. Introgen reported a net loss of $6.2 million, or $0.29 per share, for the quarter ended December 31, 2001, and a net loss of $12.3 million or $0.58 per share, for the 6 months ended December 31, 2001. These results compare to a net loss of $2.4 million, or $0.13 per share, for the quarter December...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2002-03-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry